Solstein Capital’s Quest Diagnostics DGX Stock Holding History

Solstein Capital’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.76K	Sell	9 -40	-82%	-$7.77K	﹤0.01%	401
2025 Q4	$8.5K	Hold	49	–	–	﹤0.01%	347
2025 Q3	$9.34K	Sell	49 -66	-57%	-$11.7K	﹤0.01%	338
2025 Q2	$20.7K	Buy	115 +106	+1,178%	+$18.4K	0.01%	280
2025 Q1	$1.52K	Hold	9	–	–	﹤0.01%	305
2024 Q4	$1.36K	Hold	9	–	–	﹤0.01%	304
2024 Q3	$1.4K	Hold	9	–	–	﹤0.01%	304
2024 Q2	$1.23K	Hold	9	–	–	﹤0.01%	306
2024 Q1	$1.2K	Hold	9	–	–	﹤0.01%	303
2023 Q4	$1.24K	Hold	9	–	–	﹤0.01%	301
2023 Q3	$1.1K	Hold	9	–	–	﹤0.01%	305
2023 Q2	$1.26K	Hold	9	–	–	﹤0.01%	300
2023 Q1	$1.27K	Hold	9	–	–	﹤0.01%	268
2022 Q4	$1.41K	Hold	9	–	–	﹤0.01%	278
2022 Q3	$1K	Hold	9	–	–	﹤0.01%	297
2022 Q2	$1K	Hold	9	–	–	﹤0.01%	339
2022 Q1	$1K	Hold	9	–	–	﹤0.01%	372
2021 Q4	$2K	Sell	9 -1,040	-99%	-$158K	﹤0.01%	397
2021 Q3	$152K	Buy	1,049 +1,040	+11,556%	+$152K	0.09%	150
2021 Q2	$1K	Hold	9	–	–	﹤0.01%	430
2021 Q1	$1K	Buy	+9	New	+$1.11K	﹤0.01%	379
2020 Q4	–	Sell	-9	Closed	-$1K	–	121
2020 Q3	$1K	Hold	9	–	–	﹤0.01%	199
2020 Q2	$1K	Hold	9	–	–	﹤0.01%	207
2020 Q1	$1K	Buy	+9	New	+$932	﹤0.01%	245

Other funds holding DGX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

Solstein Capital's DGX Position: Q1 2026 in Review

Solstein Capital reduced its Quest Diagnostics (DGX) stake by 82% in Q1 2026, selling an estimated $7.77K and leaving 9 shares worth $1.76K. The position accounts for ﹤0.01% of the portfolio, ranked #401.

Solstein Capital first reported a position in DGX in Q1 2020 and has held it in 24 quarters since. The position peaked at $152K in Q3 2021. 1,064 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

Solstein Capital held 9 shares of Quest Diagnostics worth $1.76K as of Q1 2026.
Solstein Capital sold 40 Quest Diagnostics shares in Q1 2026, an estimated $7.77K.
Quest Diagnostics made up ﹤0.01% of Solstein Capital's portfolio in Q1 2026, its #401 holding.
Solstein Capital first reported a position in Quest Diagnostics in Q1 2020 and has held it in 24 quarters since.
Solstein Capital's Quest Diagnostics position peaked at $152K in Q3 2021.
1,064 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on Solstein Capital's 13F filing for Q1 2026, filed 14 May 2026.